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Lemur tyrosine kinase-2 signalling regulates kinesin light
chain-2 phosphorylation and binding of Smad2 cargo
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Abstract
A recent genome wide association study identified the gene encoding lemur tyrosine kinase-2
(LMTK2) as a susceptibility gene for prostate cancer. The identified genetic alteration is within
intron 9 but the mechanisms by which LMTK2 may impact upon prostate cancer are not clear
because the functions of LMTK2 are poorly understood. Here, we show that LMTK2 regulates a
known pathway that controls phosphorylation of kinesin-1 light chain-2 (KLC2) by glycogen
synthase kinase-3ͤ (GSK3ͤ). KLC2 phosphorylation by GSK3ͤ induces release of cargo from
KLC2. LMTK2 signals via protein phosphatase-1C (PP1C) to increase inhibitory phosphorylation
of GSK3ͤ on serine-9 that reduces KLC2 phosphorylation and promotes binding of the known
KLC2 cargo Smad2. Smad2 signals to the nucleus in response to transforming growth factor-ͤ
(TGFͤ) receptor stimulation and transport of Smad2 by kinesin-1 is required for this signalling.
We show that siRNA loss of LMTK2 not only reduces binding of Smad2 to KLC2 but also
inhibits TGFͤ-induced Smad2 signalling. Thus, LMTK2 may regulate the activity of kinesin-1
motor function and Smad2 signalling.
Keywords
Glycogen synthase kinase-3ͤ; protein phosphatase-1C; transforming growth factor-ͤ;
amyotrophic lateral sclerosis; Alzheimer’s disease; axonal transport
Introduction
Lemur tyrosine kinase-2 (LMTK2) also known as brain-enriched kinase (BREK), apoptosis-
associated tyrosine kinase-2 (AATYK2), kinase/phosphatase/inhibitor-2 (KPI-2), cdk5/p35
regulated kinase (cprk) and KIAA1079 is member of the lemur family of kinases (Kawa et
al., 2004; Kesavapany et al., 2003; Wang and Brautigan 2002). These are a structurally
unique group of membrane-associated kinases comprising LMTK1, LMTK2 and LMTK3.
All are anchored in the membrane by two predicted membrane spanning regions located at
their extreme amino-termini (a splice isoform of LMTK1 lacks these sequences but
associates with membranes by palmitoylation) and contain an amino-terminally located
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kinase domain with a long carboxy-terminal “tail” (Tomomura et al., 2007). As such, they
have been named after lemurs, the long tailed Madagascan primates. Although originally
predicted to be a dual-specificity serine-threonine/tyrosine kinase, several studies have
shown that LMTK2 only targets serine and threonine residues (Kawa et al., 2004; Wang and
Brautigan 2002; Wang and Brautigan 2006).
Recently, LMTK2 has become the focus of interest with its identification as a susceptibility
gene for prostate cancer (Eeles et al., 2008; Fitzgerald et al., 2009; Waters et al., 2009).
Somatic mutations in LMTK2 have also been described in other cancers (Greenman et al.,
2007). The identified genetic alteration is within intron 9 of the LMTK2 gene but the
mechanism by which this increases the risk for prostate cancer is unknown. This is largely
because the functions of LMTK2 are not properly understood. LMTK2 knockout mice are
viable but males are infertile due to defects in spermatogenesis involving development of the
acrosome (Kawa et al., 2006). However, LMTK2 is expressed in most if not all tissues and
this suggests that it has other physiological roles (Kawa et al., 2004; Kesavapany et al.,
2003; Tomomura et al., 2007; Wang and Brautigan 2002). Indeed, there is evidence that
LMTK2 is involved in endocytic recycling and in neurons, in nerve growth factor signalling
and neurite outgrowth although the precise mechanisms by which it impacts on these
processes are unclear (Chibalina et al., 2007; Inoue et al., 2008; Kawa et al., 2004).
One clue to LMTK2 function comes from the findings that it interacts with both the cyclin
dependent kinase-5 (cdk5) activator p35 and PP1C (Kesavapany et al., 2003; Wang and
Brautigan 2002). cdk5/p35 and PP1C together function in a pathway that regulates
intracellular transport of cargoes on kinesin-1 molecular motors in neurons (Morfini et al.,
2004). Kinesin-1 is a ubiquitously expressed molecular motor that drives transport of
cargoes along microtubules. Functionally, most kinesin-1 comprises a heterotetramer of two
kinesin-1 motor proteins (also known as kinesin heavy chains) and two associated kinesin-1
light chains (KLC); KLC1 and KLC2 are the two best characterised light chain isoforms and
are encoded by separate genes (DeBoer et al., 2008; Hirokawa et al., 2009; Rahman et al.,
1998). Whilst some cargoes can attach directly to kinesin-1 motors, many associate with the
motor via KLC1 or KLC2 (Hirokawa et al., 2009). As such, the mechanisms that mediate
binding and release of cargoes from KLC1/KLC2 represent routes for controlling kinesin-1
directed intracellular transport; phosphorylation of KLC1 and KLC2 is one such route
(Morfini et al., 2002; Morfini et al., 2004; Vagnoni et al., 2011).
GSK3ͤ phosphorylates KLC2 to cause release of cargo; as such, GSK3ͤ activity inhibits
kinesin-1 transport of at least some cargoes (Morfini et al., 2002). In addition, a neuronal
signalling pathway to control GSK3ͤ phosphorylation of KLC2 has been described. This
involves cdk5/p35 mediated inhibitory phosphorylation of PP1C on threonine-320
(PP1Cthr320) which in turn induces inhibitory phosphorylation of GSK3ͤ on serine-9
(GSK3ͤser9). cdk5/p35 thus inhibits GSK3ͤ phosphorylation of KLC2 and so promotes
cargo binding and transport by kinesin-1 motors (Morfini et al., 2004). Whether cdk5/p35
directly phosphorylates PP1Cthr320 or whether it induces phosphorylation via some as yet
unidentified kinase is unclear (Li et al., 2007; Morfini et al., 2004). Whatever the precise
mechanism, phosphorylation of PP1Cthr320 in non-neuronal cells must involve an
alternative kinase since cdk5/p35 activity is mainly restricted to neurons and muscle (Fu et
al., 2001; Lew et al., 1994; Tsai et al., 1994).
Here, we show that LMTK2 also signals via PP1Cthr320 and GSK3ͤser9 phosphorylation to
regulate KLC2 phosphorylation, and that LMTK2 promotes binding of the known KLC2
cargo Smad2 to KLC2. Smad2 signals to the nucleus in response to TGFͤ receptor
stimulation and transport of Smad2 by kinesin-1 is required for this signalling. We also
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show that siRNA knockdown of LMTK2 inhibits Smad2 signalling in response to TGFͤ. As
such, our results provide a novel function for LMTK2 in regulating intracellular transport.
Results
LMTK2 interacts with PP1C and induces inhibitory phosphorylation of PP1Cthr320
We screened a human brain yeast two-hybrid library with the intracellular domain of
LMTK2 as previously described (Chibalina et al., 2007). From this screen, we obtained a
single almost full-length PP1C clone (PP1C residues 5 to the C-terminus). To confirm that
LMTK2 interacts with PP1C, we performed immunoprecipitation assays from myc-tagged
LMTK2 and PP1C co-transfected HeLa cells using anti-myc to pull-down transfected
LMTK2. PP1C co-immunoprecipitated with LMTK2 from LMTK2 but not PP1C only
transfected cells (Supplementary Figure 1A). In addition, LMTK2 contains a known PP1C
binding motif (valine-threonine-phenylalanine; residues 1325-1327 in mouse LMTK2) and
mutation of this site to alanine-threonine-alanine (LMTK2ala1325/1327) abolished the
interaction of LMTK2 with PP1C in the immunoprecipitation assays (Supplementary Figure
1A).
PP1C activity is negatively regulated by phosphorylation of threonine320 (Dohadwala et al.,
1994). We tested whether LMTK2 phosphorylates PP1Cthr320 by monitoring
phosphorylation of this site using a phospho-specific PP1Cthr320 antibody in cells co-
transfected with PP1C and either LMTK2, LMTK2ala1325/1327 or control vector.
Transfection of LMTK2 has been shown to induce increased cellular LMTK2 activity
(Kesavapany et al., 2003). Transfection of LMTK2 but not LMTK2ala1325/1327 increased
phosphorylation of PP1Cthr320 (Supplementary Figure 1B). The PP1C binding motif in
LMTK2 (residues 1325-1327) is localised some distance from the LMTK2 kinase domain
(residues 136-406) and we confirmed that this mutation did not influence LMTK2 activity
by performing in vitro kinase assays with phosphorylase b as a substrate; phosphorylase b is
a known in vitro LMTK2 substrate (Wang and Brautigan 2006). Both LMTK2 and
LMTK2ala1325/1327 displayed equivalent activities in these assays (Supplementary Figure
1C). To complement the above studies, we also monitored how siRNA-induced loss of
LMTK2 influenced phosphorylation of PP1Cthr320. Four different LMTK2 siRNAs all
markedly reduced LMTK2 levels and this led to a corresponding decrease in PP1Cthr320
phosphorylation (Figure 1A). This effect on PP1C was not seen in cells treated with two
different control siRNAs or with two different LMTK2 mis-match siRNAs, none of which
influenced LMTK2 expression (Figure 1A).
Thus, LMTK2 interacts with PP1C via sequences including its consensus PP1C binding
motif, and induces inhibitory phosphorylation of PP1Cthr320. These findings are consistent
with previous observations that identified LMTK2 as a PP1C binding partner via alternative
methods and which likewise demonstrated that LMTK2 phosphorylates PP1Cthr320 (Wang
and Brautigan 2002).
LMTK2 inhibits phosphorylation of GSK3ȕser9
PP1C controls GSK3ͤ activity by modulating phosphorylation of GSK3ͤser9 (Hernandez et
al., 2010; Morfini et al., 2004). Phosphorylation of GSK3ͤser9 inhibits GSK3ͤ activity
(Cross et al., 1995; Stambolic and Woodgett 1994; Sutherland et al., 1993). Moreover,
increasing cellular PP1Cthr320 phosphorylation (which reduces PP1C activity) induces a
corresponding increase in GSK3ͤser9 phosphorylation (Morfini et al., 2004). Since LMTK2
regulates PP1Cthr320 phosphorylation, we therefore enquired whether it might also regulate
GSK3ͤser9 phosphorylation. To do so, we modulated LMTK2 expression in HeLa cells and
monitored PP1Cthr320 phosphorylation by immunoblotting. Transfection of LMTK2 but not
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LMTK2ala1325/1327 increased GSK3ͤser9 phosphorylation (Figure 1B). We also monitored
the effect of inhibiting PP1C on LMTK2-induced phosphorylation. To do so we treated cells
with tautomycetin which is a specific inhibitor of PP1 but not PP2A (Mitsuhashi et al.,
2001). Tautomycetin increased GSK3ͤser9 phosphorylation in a fashion similar to LMTK2
and transfection of LMTK2 did not increase further this phosphorylation (Figure 1C).
Finally, we monitored the effect of reducing LMTK2 expression on GSK3ͤser9
phosphorylation. Knockdown of LMTK2 expression using four different siRNAs all
decreased GSK3ͤser9 phosphorylation (Figure 1A). Thus, elevation and siRNA knockdown
of LMTK2 expression induce complementary changes in phosphorylation of both
PP1Cthr320 and GSK3ͤser9.
LMTK2 regulation of GSK3ȕser9 involves PP1C
The above results are consistent with a model whereby LMTK2 exerts its effect on
GSK3ͤser9 via inhibitory phosphorylation of PP1Cthr320 and are analogous to previous
studies which show that cdk5/p35 regulation of GSK3ͤser9 phosphorylation also involves
PP1Cthr320 phosphorylation in neurons (Morfini et al., 2004). Indeed the lack of effect of
LMTK2ala1325/1327 (which is active but does not bind PP1C (Supplementary Figure 1)) on
GSK3ͤser9 phosphorylation provides strong evidence for an involvement of PP1C in this
process. However, to further eliminate the possibility that LMTK2 directly phosphorylates
GSK3ͤser9, we conducted in vitro phosphorylation studies with LMTK2 and recombinant
GSK3ͤ. LMTK2 was isolated by immunoprecipitation from LMTK2 transfected cells and
equal proportions of the immunoprecipitated kinase then incubated with recombinant
GSK3ͤ or phosphorylase b substrates. In these experiments, LMTK2 phosphorylated
phosphorylase b (a known LMTK2 substrate (Wang and Brautigan 2006)) but not GSK3ͤ
(Figure 2A, B). In addition, we monitored GSK3ͤser9 phosphorylation in LMTK2 siRNA
treated cells that were also treated with the PP1 inhibitor tautomycetin. If LMTK2 regulates
GSK3ͤ activity via an effect on PP1C, then the reduced phosphorylation of GSK3ͤser9 seen
in LMTK2 siRNA treated cells should be abolished in cells also treated with tautomycetin.
This proved to be the case. Thus tautomycetin increased GSK3ͤser9 phosphorylation but
siRNA knockdown of LMTK2 in these cells had no effect on this increase. By contrast, in
the absence of tautomycetin, LMTK2 knockdown decreased GSK3ͤser9 phosphorylation
(Figure 2C). As a control for this experiment, we monitored phosphorylation of c-jun N-
terminal kinase (JNK) in the different samples. Phosphorylation of JNK is also regulated by
PP1 (Mitsuhashi et al., 2003) but there is no evidence to link this phosphorylation with
LMTK2. Treatment with tautomycetin increased JNK phosphorylation as previously
described (Mitsuhashi et al., 2003) but siRNA knockdown of LMTK2 had no effect on this
phosphorylation (Figure 2C). Thus, the effect of LMTK2 on GSK3ͤser9 phosphorylation
involves PP1C.
LMTK2 induces dephosphorylation of KLC2 and promotes binding of Smad2, a known
KLC2 cargo
GSK3ͤ phosphorylation of KLC2 is regulated by a pathway involving phosphorylation of
PP1Cthr320 and GSK3ͤser9 (Morfini et al., 2004). We therefore enquired whether LMTK2
might signal to regulate KLC2 phosphorylation. To do so, we first modulated LMTK2
expression in cells and monitored phosphorylation of transfected FLAG-tagged KLC2.
Since the full complement of KLC2 sites phosphorylated by GSK3ͤ in vivo are not known
and since there are no phospho-specific antibodies that detect KLC2 phosphorylated on
these sites, we monitored phosphorylation by use of Pro-Q Diamond staining of gels (Martin
et al., 2003) following isolation of KLC2 by immunoprecipitation using anti-FLAG
antibody. Pro-Q Diamond has now been used in numerous studies to monitor changes in
protein phosphorylation (e.g. (Rahman-Roblick et al., 2008)).
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Co-transfection of FLAG-KLC2 with LMTK2 but not LMTK2ala1325/1327 decreased KLC2
phosphorylation (Figure 3A). By contrast, siRNA knockdown of LMTK2 led to an increase
in KLC2 phosphorylation (Figure 3B). Moreover, this increase in KLC2 phosphorylation
seen in LMTK2 siRNA treated cells was abolished in cells also treated with tautomycetin
(Figure 3B). The lack of effect of LMTK2ala1325/1327 on KLC2 phosphorylation and the
abrogation of the LMTK2 siRNA effect on KLC2 phosphorylation with tautomycetin
together provide strong support for the notion that the inhibitory effect of LMTK2 on KLC2
phosphorylation involves PP1C.
Since phosphorylation of KLC2 is a mechanism for controlling its interaction with cargoes
(Morfini et al., 2002), we investigated how LMTK2 influenced binding of KLC2 to Smad2.
Smad2 is known kinesin-1 cargo and KLC2 binding partner (Batut et al., 2007). Smad2 co-
immunoprecipitated with FLAG-KLC2 from co-transfected cells which is in agreement with
previous studies (Batut et al., 2007) (Figure 4A). However, co-transfection of LMTK2 to
elevate expression led to an increase in the amount of Smad2 that co-immunoprecipitated
with KLC2 (Figure 4A). By contrast, siRNA knockdown of LMTK2 reduced the amount of
Smad2 bound to KLC2 in these immunoprecipitation assays and this effect was abrogated in
cells also treated with Inhibitor VIII, a specific GSK3ͤ inhibitor (Bhat et al., 2003) (Figure
4B). Thus, LMTK2 negatively regulates KLC2 phosphorylation and promotes its binding to
Smad2, a known KLC2 cargo.
siRNA knockdown of LMTK2 inhibits TGFȕ-induced Smad2 signalling
Smad2 signals to the nucleus following TGFͤ receptor stimulation. In response to TGFͤ,
Smad2 is phosphorylated on C-terminal residues and translocates to the nucleus to regulate
the transcription of Smad2-responsive genes (see for review (Ross and Hill 2008)). Correct
transport of Smad2 by kinesin-1 is required for Smad2 signalling (Batut et al., 2007). Since
LMTK2 regulates binding of Smad2 to KLC2, we therefore enquired whether siRNA loss of
LMTK2 influenced TGFͤ-induced Smad2 phosphorylation, nuclear accumulation and
transcriptional activity. Treatment of HeLa cells with TGFͤ increased endogenous Smad2
C-terminal phosphorylation without influencing total Smad2 levels and this effect was
inhibited by siRNA knockdown of LMTK2 (Figure 5A). To investigate the effect of
LMTK2 on TGFͤ-induced Smad2 nuclear accumulation, the subcellular distribution of
Smad2 was monitored by immunostaining. TGFͤ treatment induced nuclear accumulation
of endogenous Smad2 in cells transfected with control siRNA but this accumulation was
inhibited in LMTK2 siRNA knockdown cells (Figure 5B). We also investigated how
LMTK2 influenced Smad2-mediated transcription. To do so, we quantified transcriptional
activity of a Smad2 responsive luciferase reporter gene (2xARE-Luc) in response to TGFͤ
stimulation in HeLa cells. TGFͤ increased 2xARE-Luc activity in cells treated with control
siRNA but this increase was significantly reduced in LMTK2 siRNA knockdown cells
(Figure 5C).
Two gene targets for TGFͤ/Smad signaling are the cyclin dependent kinase (cdk) inhibitors
p15Ink4B and p21WAF1/Cip1 (Reynisdottir et al., 1995). The anti-oncogenic effect of
TGFͤ can thus be mediated, at least in part by increased expression of p15Ink4B and
p21WAF1/Cip1 which both inhibit cell proliferation (Lee and Yang 2001). We therefore
enquired whether siRNA loss of LMTK2 influenced expression of p15Ink4B and
p21WAF1/Cip1. In agreement with previous studies (Reynisdottir et al., 1995), TGFͤ
increased expression of both p15Ink4B and p21WAF1/Cip1 but LMTK2 knockdown
reduced this effect (Figure 5A). Thus, siRNA knockdown of LMTK2 inhibits TGFͤ-induced
Smad2 phosphorylation and nuclear signalling including expression of the cdk inhibitory
proteins p15Ink4B and p21WAF1/Cip1.
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Discussion
Here, we show that LMTK2 regulates a pathway that controls KLC2 phosphorylation and
binding of Smad2 cargo. The pathway involves LMTK2 phosphorylation of PP1Cthr320 to
inhibit PP1C activity. Loss of PP1C activity then induces inhibitory phosphorylation of
GSK3ͤser9 and a reduction in KLC2 phosphorylation. This lowering of KLC2
phosphorylation promotes binding of Smad2 (Figure 6). A similar pathway involving cdk5/
p35 regulation of PP1C, GSK3ͤ and KLC2 phosphorylation has been described in neurons
(Morfini et al., 2004). Since LMTK2 also binds to p35 (Kesavapany et al., 2003), it is
possible that LMTK2 may at least in part mediate this neuronal cdk5/p35 effect on KLC2
phosphorylation (Morfini et al., 2004). KLC2 is widely expressed and kinesin-1 motors
function in most if not all cell-types but cdk5 is not active in non-neuronal cells due to the
absence of p35 (Fu et al., 2001; Lew et al., 1994; Tsai et al., 1994). Signalling to control
phosphorylation of KLC2 by GSK3ͤ cannot therefore involve cdk5/p35 in non-neuronal
cells. It thus seems likely that LMTK2 controls GSK3ͤ phosphorylation of KLC2 in these
non-neuronal cell-types.
One experimental approach we utilised was to monitor PP1Cthr320 and GSK3ͤser9
phosphorylation in cells in which LMTK2 expression was reduced using siRNAs. Despite
highly efficient knockdown of LMTK2, phosphorylation of both PP1Cthr320 and
GSK3ͤser9 was lowered but not eliminated. These observations suggest that there are other
pathways that control PP1Cthr320 phosphorylation and its regulation of GSK3ͤser9. Indeed,
PP1Cthr320 is also phosphorylated in non-neuronal cells such as used here by cdc2 and Nek2
(Dohadwala et al., 1994; Guo et al., 2002; Helps et al., 2000; Kwon et al., 1997).
Phosphorylation of KLC2 by GSK3ͤ negatively regulates binding of cargoes and hence
their transport on kinesin-1 motors (Morfini et al., 2002). We show here that LMTK2
impacts on this process to influence binding of Smad2 to KLC2. Smad2 is a known KLC2
binding partner and kinesin-1 cargo (Batut et al., 2007). Kinesin-1 is a major molecular
motor that mediates intracellular transport of numerous cargoes including intermediate
filaments, mitochondria and a variety of vesicle subtypes (Hirokawa et al., 2009). Since
there is evidence that phosphorylation of KLC2 by GSK3ͤ affects binding of multiple
cargoes (Morfini et al., 2002), it seems likely that LMTK2 may likewise influence binding
of cargoes other than Smad2. LMTK2 may thus affect a number of physiological processes
requiring kinesin-1 based motility.
Smad2 is required for transduction of TGFͤ signals. TGFͤ induces nuclear translocation of
Smad2 which in turn regulates expression of TGFͤ-responsive genes (see for reviews (Hill
2009; Massague et al., 2005; Massague and Gomis 2006)). Smad2 is transported on
kinesin-1 motors through the cytoplasm and this transport is essential for Smad2 nuclear
signalling (Batut et al., 2007). We show that siRNA loss of LMTK2 not only reduces
binding of Smad2 to KLC2 but also inhibits Smad2 nuclear signalling in response to TGFͤ.
Thus, loss of LMTK2 inhibits TGFͤ-induced Smad2 phosphorylation, nuclear accumulation
and transcription of a Smad2 reporter gene. We also show that LMTK2 loss inhibits
expression of the cdk inhibitors p15Ink4B and p21WAF1/Cip1 in response to TGFͤ. Some
of the anti-oncogenic effects of TGFͤ are believed to be mediated by expression of these
cdk inhibitory proteins (Lee and Yang 2001; Reynisdottir et al., 1995).
Loss of LMTK2 inhibited but did not abrogate Smad2 nuclear signalling. Since siRNA
knockdown of LMTK2 was highly efficient, it is possible that there are other processes that
may impact upon kinesin-1 transport of Smad2. Indeed, there are two KLC isoforms (KLC1
and KLC2) and only KLC2 is a target for phosphorylation by GSK3ͤ; LMTK2 regulation of
GSK3ͤ activity will thus not influence any binding of Smad2 to KLC1. Also, the C-terminal
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domains of KLCs (which is where the GSK3ͤ phosphorylation sites in KLC2 are believed
to be located (Morfini et al., 2002)) are altered by alternative splicing of mRNAs and this
also influences binding of cargoes (Wozniak and Allan 2006). These other regulatory
mechanisms may also influence kinesin-1 transport of Smad2 and Smad2 signalling.
TGFͤ signalling functions in a variety of processes including cell division, differentiation,
cell migration, inflammation and apoptosis (Massague et al., 2005; Massague and Gomis
2006). Altered TGFͤ/Smad signalling has also been associated with a number of human
diseases. These include some neurodegenerative diseases such as Alzheimer’s disease and
amyotrophic lateral sclerosis (ALS) (Katsuno et al., 2011; Town et al., 2008). Interestingly,
defective axonal transport of kinesin-1 cargoes is a prominent pathological feature of these
disorders (De Vos et al., 2008) and disruption to cdk5/p35 (which phosphorylates LMTK2
to regulate its activity) is also seen in Alzheimer’s disease and ALS (Bajaj et al., 1999;
Kesavapany et al., 2003; Su and Tsai 2011). As such, altered LMTK2 function may
contribute to some neurodegenerative diseases.
In addition, TGFͤ/Smad signalling has been associated with a variety of cancers (see for
review (Massague 2008). In normal and premalignant cells, TGFͤ suppresses tumor
formation but in later stages of tumorigenesis, TGFͤ signalling may be detrimental and
facilitate malignant progression (Massague 2008).
The effects of the LMTK2 intron 9 genetic alteration associated with prostate cancer on
LMTK2 function are not known. However, recent evidence indicates that LMTK2
expression may be significantly reduced in malignant prostate cancer tissues and that this
may be due to the intron 9 change (Harries et al., 2010). If this proves to be the case, then
LMTK2 stimulation of Smad2 binding to KLC2 and transport on kinesin-1 may be inhibited
in prostate cancer cells. In addition, LMTK2 has recently been shown to associate with
myosin VI and to regulate its function in cellular transport (Chibalina et al., 2007; Inoue et
al., 2008). Altered expression of myosin VI has also been seen in prostate cancer (Puri et al.,
2010; Su et al., 2001). Thus, LMTK2 modulates the function of two different molecular
motors whose functions may impact on prostate cancer.
Materials and Methods
Antibodies
The following antibodies were used: anti-Myc-tag (9B11), anti-Phospho-PP1Cͣ (Thr320),
anti-Phospho-GSK3ͤ(Ser9), anti-Phospho-SAPK/JNK, anti-SAPK/JNK, anti-Smad2
(86F7), anti-Phospho-Smad2(Ser465/467) (138D4), anti-p15INK4B (all from Cell Signaling
Technology, Danvers, MA); anti-PP1Cͣ (E-9) (Santa Cruz Biotechnology, Santa Cruz,
CA); anti-GSK3ͤ and anti-Smad2/3 (BD Biosciences, Franklin Lakes, NJ); anti-FLAG
(M5) (Sigma, Poole, UK); anti-p21/WAF1/Cip1 (Abcam, Cambridge, UK). The rabbit
LMTK2 polyclonal antibody was as described (Chibalina et al., 2007).
Plasmids
LMTK2 cDNA was generated from CD1 mouse brain by RT-PCR using a SuperScript® III
Platinum® RT-PCR kit (Invitrogen, Paisley, UK) using the following primer set: 5ᓉ-
GACCGCGCGGTGGACGAGATG-3ᓉ and 5ᓉ-GGAGTGGATTGCGTTGCTCAGGTG-3ᓉ.
A myc tag was inserted onto the C-terminus by PCR and LMTK2-myc cloned into pCIneo
(Promega, Southampton, UK). To generate the LMTK2ala1325/1327, LMTK2 valine1325 and
phenylalanine1327 were both mutated to alanine using a QuikChange XL Site-Directed
Mutagenesis Kit (Stratagene, Amsterdam, The Netherlands) and the following primer set:
5ᓉ-GGAAGAAGGAAAAGAAGGCAGCGACAGCTTTCGATGATGTCACCG-3ᓉ and 5ᓉ-
CGGTGACATCATCGAAAGCTGTCGCTGCCTTCTTTTCCTTCTTCC-3ᓉ. Human
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PP1Cͣ in pCMV6-XL4 was from Origene (Rockville, MD). KLC2 cDNA was from Source
Bioscience (Nottingham, UK); an amino-terminal FLAG tag was added by PCR and FLAG-
KLC2 cloned into pCIneo. Plasmids for GFP-Smad2, GSK3ͤ, forkhead activin signal
transducer FAST1 (FoxH1) and 2xARE-Luc were as described previously (Batut et al.,
2007; Lovestone et al., 1994; Noda et al., 2006; Zhou et al., 1998). pRL-TK Renilla
luciferase reporter control plasmid was from Promega. For controls and so that all
transfections received the same amounts of DNA, pCIneo vector containing the E. coli
chloramphenicol acetyltransferase (CAT) was used as described (Guidato et al., 1998).
Yeast two-hybrid screen
The yeast two-hybrid screen was performed using a pre-transformed human brain cDNA
library (Clontech, Mountain View, CA) with the cytoplasmic domain of LMTK2 (amino
acids 67-1443) as the “bait” cloned into pY1 (Chibalina et al., 2007). Methods were
according to the instructions provided by Clontech. Following mating yeast underwent tryp-/
leu-/his- selection and vigorously growing clones were subjected to ͤ-galactosidase assays.
Prey plasmids were rescued by transformation into E. coli and positive plasmids identified
by co-transformation back into yeast either alone or with LMTK2 bait as described
elsewhere (McLoughlin and Miller 1996).
Cell Culture and transfection
HeLa cells were cultured in DMEM containing 10% fetal bovine serum and 2 mM L-
glutamine (Invitrogen). Cells were transfected using Exgen 500 (Fermentas, Burlington,
Ontario, Canada) according to the manufacturer’s instructions except for
immunofluorescence and reporter gene assays where Lipofectamine 2000 (Invitrogen) was
used, again according to the manufacturers instructions. Lipofectamine 2000 was used for
immunostaining since Exgen can give background staining with 4ᓉ,6-diamidino-2-
phenylindole (DAPI) which was used as a nuclear label (see Immunofluorescence studies
below). For siRNA knock-downs, cells were transfected with Oligofectamine (Invitrogen)
according to the manufacturer’s instructions. Human LMTK2 was targeted with 4 different
siRNAs that were all obtained from ThermoFisher (Lafayette, CO): 2068 (5ᓉ-
UCAGGAGCGUUGAACUUGA-3ᓉ), 1158 (5ᓉ-GCAGGUACAAGGAGGAUUA-3ᓉ), 1262
(5ᓉ-GCAGAUCAGACUAAGUAUA-3ᓉ) and 1972 (5ᓉ-
GUAGUAACUUGGAGCUUGA-3ᓉ). Unless indicated, all four siRNAs were used in
combination and these gave knockdowns that were equivalent or greater than the individual
siRNAs; this is in agreement with previous studies that also used these siRNAs (Chibalina et
al., 2007). Control siRNAs were also from ThermoFisher. Cells were harvested for analyses
4 days after siRNA treatment. Where described, cells were treated with 5 ͮM tautomycetin
(Merck Chemical Ltd., Beeston, UK) or 1 ͮM GSK3ͤ inhibitor VIII (AR-A014418; N-(4-
Methoxybenzyl)-N’-(5-nitro-1,3-thiazol-2-yl)urea) for 5 hours prior to harvesting. TGFͤ
(Sigma) was used at 1 ng/ml for the times indicated.
SDS-PAGE and immunoblotting
Cells were harvested for SDS-PAGE by washing with phosphate buffered saline pre-
warmed at 37°C and scraping into SDS-PAGE sample buffer and immediately heating to
100°C. Samples were separated on 8% or 10% (w/v) acrylamide gels, transferred to Protran
nitrocellulose membranes (Schleicher & Schuell, Dassel, Germany) using a Transblot
system (BioRad, Hercules, CA) and following blocking, probed with primary antibodies.
Following washing, the blots were incubated with horseradish peroxidase-conjugated goat
anti-mouse or anti-rabbit Igs and developed using an enhanced chemiluminescence system
(GE Healthcare, Piscataway, NJ).
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Immunoprecipitation and Pro-Q Diamond staining
Immunoprecipitation assays were performed essentially as described (Vagnoni et al., 2011).
Briefly cells were lysed in ice-cold immunoprecipitation (IP) buffer comprising 20 mM
HEPES pH 7.4, 100 mM NaCl, 1% Triton X100, 10% Glycerol, 5 mM EDTA, 0.5 mM
sodium orthovanadate, 25 mM sodium fluoride, 20 mM ͤ-glycerophosphate and protease
inhibitors (Complete, Roche, Burgess Hill, UK) for 30 minutes. Following centrifugation at
16,000 X g for 30 min at 4°C, the supernatants were precleared with protein G-Sepharose
beads (Sigma) for 1 hour at 4°C and then incubated with primary antibodies for 16 hours at
4°C. Antibodies were captured with protein G-Sepharose beads and following washing with
IP buffer, bound proteins were eluted by incubation in SDS-PAGE sample buffer and
heating at 100°C. Samples were then analysed by immunoblotting and Pro-Q Diamond
staining. For Pro-Q Diamond staining, gels were incubated with Pro-Q Diamond
phosphoprotein gel stain (Invitrogen) according to the manufacturer’s instructions and
signals captured using an Ettan DIGE Imager (GE Healthcare).
In vitro phosphorylation studies
Comparative in vitro phosphorylation studies of phosphorylase b (Sigma) by LMTK2 and
LMTK2ala1325/1327 were performed essentially as described (Kesavapany et al., 2003).
Briefly, LMTK2 or LMTK2ala1325/1327 was isolated by immunoprecipitation from either
LMTK2 or LMTK2ala1325/1327 transfected cells using antibody 9B11 to the myc tag.
LMTK2/LMTK2ala1325/1327 were then incubated with 2 ͮg of phosphorylase b, 0.185 MBq
[ͥ32P]ATP in 25 mM Tris-HCl pH 7.5 containing 10 mM MgCl2, 5 mM ͤ-
glycerophosphate, 0.1 mM sodium orthovanadate, 2 mM dithiothreitol and 20 ͮM ATP for
20 minutes at 30°C in a final volume of 30 ͮl. The reactions were stopped by adding SDS-
PAGE sample buffer and heating to 100°C. Samples were separated by SDS-PAGE and the
gels stained with Coomassie blue (Sigma) and subjected to autoradiography. For studies
testing LMTK2 phosphorylation of GSK3ͤ, LMTK2 was again isolated by
immunoprecipitation from LMTK2 transfected cells using antibody 9B11 to the myc tag.
LMTK2 was then incubated with 1 ͮg of either phosphorylase b or GSK3ͤ (Cell Signaling
Technology), 0.185 MBq [ͥ32P]ATP in 25 mM Tris-HCl pH 7.5 containing 10 mM MgCl2,
5 mM ͤ-glycerophosphate, 0.1 mM sodium orthovanadate, 2 mM dithiothreitol, 20 ͮM ATP
and 1 ͮM GSK3ͤ inhibitor VIII for 20 minutes at 30°C in a final volume of 50 ͮl. GSK3ͤ
inhibitor VIII was included to inhibit any possible autophosphorylation of GSK3ͤ but was
also added to phosphorylase b reactions. The reactions were again stopped by adding SDS-
PAGE sample buffer and heating to 100°C, and equal volumes of the samples separated by
SDS-PAGE; the gels were then stained with Coomassie blue and subjected to
autoradiography.
Luciferase reporter assays
Luciferase assays were performed essentially as described by us for other reporter gene
assays (Lau et al., 2008) using a Dual-Glo luciferase assay system according to the
manufacturer’s instructions (Promega). Briefly, HeLa cells transfected with control or
LMTK2 siRNAs were cultured for 3 days. They were then transfected with reporter gene
constructs and the media replaced with DMEM containing 0.2% fetal bovine serum with or
without 1ng/ml TGFͤ and the cells cultured for a further 16 hours as described by others for
similar assays (Murakami et al., 2009; Noda et al., 2006). Cells were then harvested into Glo
lysis buffer (Promega) and the lysates transferred to a 96-well luminometer plate (Wallac).
An equal volume of Dual-Glo luciferase substrate was added and firefly luciferase activities
produced by the firefly luciferase reporter plasmid 2xARE-luc measured using a Wallac
Trilux luminometer. Renilla luciferase activities produced by the co-transfected phRL-TK
transfection efficiency control plasmid were then assayed by adding an equal volume of
Dual-Glo Stop&Glo substrate (comprising the stop solution for firefly luciferase and
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substrate for Renilla luciferase) and remeasuring in the luminometer. Firefly luciferase
activities were normalised to the corresponding Renilla luciferase activities and statistical
analyses performed using one-way ANOVA with LSD post hoc test.
Immunofluorescence studies
HeLa cells were transfected with control or LMTK2 siRNAs. 17 hours prior to analyses, the
media was replaced with DMEM containing 0.2% fetal bovine serum and the cells treated
with 1 ng/ml TGFͤ (Sigma) for 1 hour. Cells were then fixed in 4% (w/v) paraformaldehyde
in PBS for 20 minutes, permeabilised with 0.5% (w/v) Triton X-100 in PBS for 10 minutes,
blocked with 5% (v/v) foetal bovine serum in PBS for 1 hour, and then probed with anti-
Smad2 86F7 (Cell Signaling Technology) antibody diluted in blocking solution. Following
washing, the primary antibody was detected using goat anti-rabbit IgG coupled to Alexa
Fluor 568 (Molecular Probes) and the cells counterstained with 0.5 ͮg/ml 4ᓉ,6-diamidino-2-
phenylindole (DAPI) (Sigma) to visualise nuclei. Samples were mounted in Vectashield
(Vector labs) and imaged using a Leica DM5000B microscope and 40X/0.75 HCX
FLUOTAR objective (Leica Microsystems, Wetzlar, Germany). To monitor the relative
amounts of Smad2 in the cytoplasm and in nuclei, the mean Smad2 fluorescence signals
were quantified in each compartment using Image J (developed by Wayne Rasband, NIH,
Bethesda, USA; http://rsb.info.nih.gov/ij/); nuclei were defined by DAPI staining. Analyses
were performed from at least 37 cells from two different experiments. Statistical
significance was determined using one-way ANOVA with LSD post hoc test.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
siRNA knockdown of LMTK2 decreases PP1Cthr320 and GSK3ͤser9 phosphorylation and
transfection of LMTK2 but not LMTK2ala1325/1327 increases GSK3ͤser9 phosphorylation in
HeLa cells. (A) Cells were mock transfected (no siRNA), or transfected with two different
control siRNAs, two different LMTK2 mismatch siRNAs or four different LMTK2 siRNAs
as indicated. Samples were then probed on immunoblots for total PP1C (PP1C) and
phospho-PP1Cthr320 (PP1C-thr320p), total GSK3ͤ (GSK3ͤ) and phospho-GSK3ͤser9
(GSK3ͤ-ser9p), and LMTK2 as indicated. (B) shows cellular phosphorylation of
GSK3ͤser9 by LMTK2. Cells were co-transfected with GSK3ͤ and either control vector
(Ctrl), LMTK2 or LMTK2ala1325/1327 (LMTK2ala). Samples were probed on immunoblots
for total GSK3ͤ (GSK3ͤ), phosphorylated GSK3ͤser9 (GSK3ͤ-ser9p) and LMTK2 using
the myc tag. LMTK2 but not LMTK2ala1325/1327 increased phosphorylation of GSK3ͤser9.
(C) tautomycetin increases phosphorylation of GSK3ͤser9 and does not affect LMTK2-
induced phosphorylation of GSK3ͤser9. Cells were co-transfected with GSK3ͤ and either
control vector (Ctrl) or LMTK2, treated with (+) or without (−) tautomycetin (TMC) as
indicated and analysed on immunoblots for total GSK3ͤ (GSK3ͤ), phosphorylated
GSK3ͤser9 (GSK3ͤ-ser9p), and LMTK2 using the myc tag.
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Figure 2.
LMTK2 regulation of GSK3ͤser9 phosphorylation involves PP1C. (A) and (B) show in
vitro phosphorylation (ͥ32P incorporation) of phosphorylase b but not GSK3ͤ by LMTK2.
LMTK2 was isolated by immunoprecipitation from LMTK2 transfected cells using the myc
tag. Equal proportions of immunoprecipitated LMTK2 were then incubated with
phosphorylase b (A) or GSK3ͤ (B) substrates in reactions containing [ͥ32P]ATP. (−) and
(+) refer to absence or presence of myc antibody in the immunoprecipitations to isolate
active kinase. Reactions were also performed with no substrate as indicated. The upper
panels show the autoradiographs; the lower panels are the corresponding Coomassie stained
gels to show equal amounts of substrates in the reaction mixes. Phosphorylase b and GSK3ͤ
are indicated on the Coomassie gels; Ig indicates immunoglobulin heavy chain of the
immunoprecipitating antibody. Also shown (bottom panels) are immunoblots with anti-myc
to demonstrate equal amounts of LMTK2 in the reaction mixes. All autorads were exposed
for the same time. (C) shows reduced GSK3ͤser9 phosphorylation in LMTK2 siRNA
transfected HeLa cells in the absence but not presence of the PP1C inhibitor tautomycetin.
Cells were transfected with control or LMTK2 siRNAs and treated with tautomycetin as
indicated. Samples were probed on immunoblots for total GSK3ͤ (GSK3ͤ) and phospho-
GSK3ͤser9 (GSK3ͤ-ser9p) as shown. The stronger labelling for phospho-GSK3ͤser9 in the
presence of tautomycetin is consistent with a role for PP1C in regulating phosphorylation of
this site and is in agreement with previous studies (Morfini et al., 2004). Also shown are
control blots for total JNK (p46 and p54 isoforms) (JNK), phosphorylated JNK (JNK-p) and
LMTK2 to confirm knockdown. Tautomycetin increases phosphorylation of JNK but siRNA
knockdown of LMTK2 has no effect on JNK phosphorylation.
Manser et al. Page 15
Oncogene. Author manuscript; available in PMC 2012 November 30.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 3.
LMTK2 induces dephosphorylation of KLC2. (A) shows Pro-Q Diamond (Pro-Q) phospho-
staining of KLC2 isolated from HeLa cells co-transfected with KLC2 and either control
vector (Ctrl), LMTK2 or LMTK2ala1325/1327 (LMTK2ala). Transfected KLC2 was isolated
by immunoprecipitation using the FLAG tag and then analysed by Pro-Q Diamond phospho-
staining after SDS-PAGE. Also shown are immunoblots of immunoprecipitated KLC2 (to
demonstrate equal amounts of KLC2 in the different samples) and transfected LMTK2
which was detected using the myc tag. LMTK2 but not LMTK2ala1325/1327 reduces Pro-Q
Diamond staining of KLC2. (B) shows Pro-Q Diamond (Pro-Q) phospho-staining of KLC2
isolated from HeLa cells co-transfected with KLC2 and either no siRNA, control siRNA
(Ctrl siRNA), LMTK2 siRNA or LMTK2 siRNA followed by treatment with the PP1C
inhibitor tautomycetin (TMC). Transfected KLC2 was isolated by immunoprecipitation
using the FLAG tag and then analysed by Pro-Q Diamond phospho-staining after SDS-
PAGE. Also shown are immunoblots of immunoprecipitated KLC2 (to demonstrate equal
amounts of KLC2 in the different samples) and LMTK2 which was detected using anti-
LMTK2 antibody. siRNA knockdown of LMTK2 increases Pro-Q Diamond staining of
KLC2 and this effect is lost following treatment of the cells with tautomycetin.
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Figure 4.
LMTK2 increases binding of Smad2 cargo to KLC2 in HeLa cells. (A) cells were co-
transfected with KLC2 and Smad2, and either control vector (Ctrl) or LMTK2. KLC2 was
immunoprecipitated with anti-FLAG antibody and the amounts of KLC2 and co-
immunoprecipitating Smad2 then detected on immunoblots. Upper panels (IP) show the
immunoprecipitations; lower panels show the inputs in the two transfections. In the lower
panel, LMTK2 was detected using rabbit anti-LMTK2 antibody. Transfection of LMTK2
increases the amount of Smad2 bound to KLC2. (B) cells were co-transfected with KLC2
and Smad2, and either control siRNA (Ctrl), LMTK2 siRNA or LMTK2 siRNA followed by
treatment with GSK3ͤ inhibitor VIII as indicated (GSK3In −/+). KLC2 was
immunoprecipitated with anti-FLAG antibody and the amounts of KLC2 and co-
immunoprecipitating Smad2 then detected on immunoblots. Upper panels (IP) show the
immunoprecipitations; lower panels show the inputs in the two transfections. In the lower
panel, LMTK2 was detected using rabbit anti-LMTK2 antibody. siRNA knockdown of
LMTK2 decreases the amount of Smad2 bound to KLC2 and this effect is rescued in cells
treated with GSK3ͤ inhibitor VIII.
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Figure 5.
siRNA knockdown of LMTK2 inhibits TGFͤ-induced Smad2 signalling in HeLa cells. (A)
LMTK2 siRNA knockdown inhibits TGFͤ-induced phosphorylation of Smad2 and
expression of p15Ink4B and p21WAF1/Cip1. Cells were treated with either vehicle (−) or
TGFͤ (+) and the samples probed on immunoblots for phosphorylated (p-Smad2) and total
Smad2, p15Ink4B (p15), p21WAF1/Cip1 (p21) and for LMTK2. TGFͤ increases Smad2
phosphorylation and expression of p15Ink4B and p21WAF1/Cip1 in control siRNA
transfected cells (Ctrl) and these effects are inhibited in LMTK2 siRNA transfected cells.
(B) LMTK2 knockdown inhibits TGFͤ-induced nuclear accumulation of Smad2. Cells
transfected with control (Ctrl) or LMTK2 siRNAs were treated vehicle or TGFͤ as indicated
and immunostained for Smad2; nuclei were labelled with DAPI. Bar chart shows the relative
nuclear/cytoplasmic (Nucleus/Cyto) signals in the different treated cells. Statistical
significance was determined by one-way ANOVA followed by LSD post hoc test. N≥37;
error bars are SEM *** p<0.0001. Also shown is an immunoblot from cells treated at the
same time as for immunostaining to demonstrate efficient siRNA knockdown of LMTK2.
(C) LMTK2 knockdown inhibits TGFͤ-induced transcription of Smad2 reporter gene
2xARE-luc. Cells treated with control (Ctrl) or LMTK2 siRNAs were transfected with
2xARE-luc, FoxH1 and pRL-TK (Renilla luciferase) plasmids and treated with vehicle or
TGFͤ as indicated. 2xARE-luc signals were normalised to pRL-TK transfection efficiency
control signals. TGFͤ increases transcription of 2xARE-luc and this effect is inhibited in
LMTK2 siRNA knockdown cells. Statistical significance was determined by one-way
ANOVA followed by LSD post hoc test. N=24; error bars are SEM, *** p<0.0001. Also
shown is an immunoblot from cells treated at the same time as the assay to demonstrate
efficient siRNA knockdown of LMTK2.
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Figure 6.
Model showing the proposed mechanism for LMTK2 regulation of KLC2 phosphorylation
and binding of Smad2. LMTK2 directly phosphorylates PP1C on thr320 to reduce PP1C
activity (1). Reduced PP1C activity induces an increase in inhibitory GSK3ͤser9
phosphorylation (2). This lowering of GSK3ͤ activity reduces KLC2 phosphorylation (3) to
promote binding of Smad2 cargo (4).
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